Allarity Therapeutics Inc 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number: 001-41160 ALLARITY THERAPEUTICS, INC.(Exact name of registrant as specified in its charter) 87-2147982 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation or organization) 123 E Tarpon Ave, Tarpon Springs, FL 34689(Address of principal executive offices and zip code) (401) 426-4664(Registrant’s telephone number, including area code) Not Applicable(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to filesuch reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). Yes☒No☐ Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 14, 2026, there were 15,910,724shares of the issuer’s common stock, par value $0.0001, outstanding. Table of Contents Cautionary Note Regarding Forward-Looking StatementsiiPART I—FINANCIAL INFORMATION1 Item 1.Financial StatementsCondensed Consolidated Balance Sheets as at June 30, 2026 (Unaudited) and December31, 2025Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six monthsended June 30, 2026and 2025(Unaudited)Condensed Consolidated Statements of Changes in Stockholders’Equityfor the three and sixmonths endedJune 30, 2026and 2025(Unaudited)CondensedConsolidated Statements of Cash Flows for the six months ended June 30,2026 and2025(Unaudited)Notes to Condensed Consolidated Financial Statements(Unaudited)Item 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II—OTHER INFORMATION Item 1.Legal Proceedings21Item1A.Risk Factors21Item 2.Unregistered Sales of Equity Securities and Use of Proceeds22Item 3.Defaults Upon Senior Securities22Item 4.Mine Safety Disclosures22Item 5.Other Information22Item 6.Exhibits23 Unless the context indicates otherwise, references in this Quarterly Report on Form 10-Q (the “Quarterly Report”) to the“Company,” “Allarity,” “we,” “us,” “our” and similar terms refer to Allarity Therapeutics, Inc., Allarity Therapeutics A/S (aspredecessor) and its respective consolidated subsidiaries. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report contains statements we believe are “forward-looking statements” within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Those forward-looking statements are intended to enjoy the protection of the safe harborfor forward-looking statements provided by that act as well as protections afforded by other federal securities laws. Generally,words such as “achieve,” “aim,” “ambitions,” “anticipate,” “believe,” “committed,” “continue,” “could,” “designed,” “estimate,”“expect,” “forecast,” “future,” “goals,” “grow,” “guidance,” “intend,” “likely,” “may,” “milestone,” “objective,” “on track,”“opportunity,”“outlook,”“pending,”“plan,”“position,”“possible,”“potential,”“predict,”“progress,”“roadmap,”“seek,”“should,” “strive,” “targets,” “to be,” “upcoming,” “will,” “would,” and variations of such words and similar expressions identifyforward-looking statements, which are not historical in nature. Forward-looking statements may appear throughout this QuarterlyReport and other document